The challenge of cardiomyopathy

Journal of the American College of Cardiology

Volumn 13, Issue 6, 1989, Pages 1219-1239

  Abelmann, Walter H ^a   Lorell, Beverly H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMRINONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIURETIC AGENT; DOBUTAMINE; INOTROPIC AGENT; UBIDECARENONE; VASODILATOR AGENT; VERAPAMIL;

CARDIOMYOPATHY; FATALITY; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

CARDIOMYOPATHY, CONGESTIVE; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, RESTRICTIVE; DEATH, SUDDEN; EUROPE; HEART; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; HUMAN; SUPPORT, NON-U.S. GOV'T; UNITED STATES;

EID: 0024605642     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/0735-1097(89)90293-3     Document Type: Conference Paper

References (282)

1. Cardiomyopathy and myocardial involvement in systemic disease
2. Prospects and predictions for the cardiomyopathies
3. Dilated cardiomyopathies of the adult
4. Dilated cardiomyopathies of the adult
5. The cardiomyopathies
6. Classification and natural history of primary myocardial disease
7. The cardiomyopathies and myocarditides
8. Beitrag zur Kentniss der idiopathischen Herz-muskelerkrankungen
9. De l'asystolie progressive des jeunes sujets par myocardite subaigue primitive
10. Diagnosis of chronic non-valvular heart disease (chronic myocarditis)
11. The clinical and hemodynamic features of primary myocardial disease
12. The clinical spectrum of primary myocardial disease
13. Uncommon myocardial diseases. The noncoronary cardiomyopathies
14. Clinical aspects of cardiomyopathy
15. Accounts of international meetings: idiopathic cardiomegaly
16. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies
17. The etiology, pathogenesis and pathophysiology of dilated cardiomyopathies
18. The cardiomyopathies
19. Incidence of dilated cardiomyopathy
20. Prevalence of overt dilated cardiomyopathy in two regions of England
21. Cardiomyopathies: Report of a WHO expert committee
22. Hypertrophic cardiomyopathy
23. Familial cardiomyopathy
24. Functional obstruction of the left ventricle (acquired aortic subvalvular stenosis)
25. Asymmetric hypertrophy of the heart in young adults
26. Idiopathic hypertrophic subaortic stenosis: clinical, hemodynamic and angiographic manifestations
27. Idiopathic hypertrophic subaortic stenosis: clinical analysis of 126 patients with emphasis on the natural history
28. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis)
29. Operative treatment in hypertrophic subaortic stenosis: techniques, and the results of pre and post operative assessments in 83 patients
30. Quantitative analysis of the distribution of cardiac muscle cell disorganization in the left ventricular wall of patients with hypertrophic cardiomyopathy
31. Impaired rate of left ventricular filling in idiopathic hypertrophic subaortic stenosis and valvular aortic stenosis
32. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy
33. Clinical recognition of the cardiomyopathies
34. Prognosis in hypertrophic cardiomyopathy: role of age and clinical, electrocardiographic and hemodynamic features
35. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients
36. Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy
37. Hypertrophic cardiomyopathy: importance of the site and extent of hypertrophy: a review
38. Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide-angle two dimensional study of 125 patients
39. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study
40. Heterogeneous morphologic expression of genetically transmitted hypertrophic cardiomyopathy: two dimensional echocardiographic analysis
41. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients
42. Mid-ventricular obstruction: a variant of hypertrophic obstructive cardiomyopathy
43. The frontiers of cardiomyopathy
44. Hypertrophic cardiomyopathy: interrelations of clinical manifestations, pathophysiology and therapy
45. Altered left ventricular diastolic properties during pacing-induced angina in patients with aortic stenosis
46. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures
47. Coronary flow reserve and diastolic function in hypertrophic cardiomyopathy
48. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography
49. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy
50. Decreased coronary reserve: a mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries
51. Reversal of exaggerated hypoxic dysfunction in hypertrophied hearts by increased glycolytic substrate (abstr)
52. Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy
53. Pressure gradients without obstruction: a new concept of “hypertrophic subaortic stenosis”
54. Has “obstruction” hindered our understanding of hypertrophic cardiomyopathy?
55. Dynamics of left ventricular ejection in obstructive and nonobstructive hypertrophic cardiomyopathy
56. Hypertrophic cardiomyopathy: a 1987 viewpoint
57. Clinical significance and therapeutic implications of the left ventricular outflow tract pressure gradient in hypertrophic cardiomyopathy
58. Differences in coronary flow and myocardial metabolism at rest and during pacing between patients with obstructive and patients with nonobstructive cardiomyopathy
59. Cardiac hypertrophy: the consequences for diastole
60. Diastolic abnormalities in patients with hypertrophic cardiomyopathy: relation to magnitude of left ventricular hypertrophy
61. Left ventricular relaxation and filling pattern in different forms of left ventricular hypertrophy
62. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy
63. Echocardiographic assessment of left ventricular filling and septal and posterior wall dynamics in idiopathic hypertrophic subaortic stenosis
64. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy
65. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy
66. Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy altered left ventricular loading or improved muscle activation?
67. Regional left ventricular asynchrony and impaired left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil
68. Effects of long-term treatment with amiodarone on exercise hemodynamics and left ventricular relaxation in patients with hypertrophic cardiomyopathy
69. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy
70. Use of calcium channel blockers in hypertrophic cardiomyopathy
71. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy
72. Hypertrophic cardiomyopathy and sudden death
73. Arrhythmia in hypertrophic cardiomyopathy. Influence on prognosis
74. Prognostic significance of 24 hour ambulatory monitoring in patients with hypertrophic cardiomyopathy: a prospective study
75. Arrhythmia in hypertrophic cardiomyopathy: exercise and 48 hour ambulatory electrocardiographic assessment with and without beta adrenergic blocking therapy
76. Arrhythmia in hypertrophic cardiomyopathy. Comparison of amiodarone and verapamil in treatment
77. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
78. The genetics of hypertrophic cardiomyopathy
79. Inheritance of hypertrophic cardiomyopathy: a cross-sectional and M-mode echocardiographic study of 50 families
80. Hypertensive hypertrophic cardiomyopathy in the elderly
81. Elderly patients with hypertrophic cardiomyopathy: a subset with distinctive left ventricular morphology and progressive clinical course late in life
82. Idiopathic hypertrophic subaortic stenosis as observed in a large community hospital: relation to age and history of hypertension
83. HLA-DRW4 antigen linkage in patients with hypertrophic obstructive cardiomyopathy
84. Human lymphocyte antigens in hypertrophic cardiomyopathy
85. Hereditary mitochondria) hypertrophic cardiomyopathy with mitochondria) myopathy of skeletal muscle, congenital cataract and lactic acidosis
86. Hypertrophic cardiomyopathy associated with myotonic muscular dystrophy
87. Hypertrophic obstruction cardiomyopathy due to Fabry's disease
88. Pathogenesis of hypertrophic cardiomyopathy: hypothesis and speculations
89. Evidence of myocyte hyperplasia in hypertrophic cardiomyopathy and other disorders with myocardial hypertrophy?
90. Force-velocity-length relations in hypertrophic cardiomyopathy: evidence of normal or depressed myocardial contractility
91. Evaluation of left ventricular contractility in hypertrophic cardiomyopathy from end-systolic pressurevolume relation
92. Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy a biopsy study
93. Hypertrophic cardiomyopathy characterized by beta-adrenoceptor density, relative amount of betaadrenoceptor subtypes and adenylate cyclase activity
94. Cyclic nucleotide analysis of myocardial biopsies in hypertrophic cardiomyopathy
95. Hypercalcemia and idiopathic hypertrophic subaortic stenosis
96. Effects of verapamil on contraction and relaxation on cultured chick embryo ventricular cells during calcium overload
97. Calcium and cardiovascular function intracellular calcium levels during contraction and relaxation of mammalian and vascular smooth muscle as detected by aequorin
98. Altered calcium handling in experimental pressure-overload in the ferret
99. Obscure heart disease in West African troops
100. Endocarditis parietalis fibroplastica mit Bluteosinophilie
101. Relation between eosinophilia and endomyocardial disease
102. The cardiotoxicity of eosinophils
103. Restrictive and obliterative cardiomyopathy
104. Hemodynamic cardiac constriction without anatomic myocardial restriction or pericardial constriction
105. Wall thickness and diastolic properties of the left ventricle
106. Morphologic alterations of the collagen matrix with cardiac hypertrophy
107. Clinical profile of restrictive cardiomyopathy
108. Idiopathic restrictive cardiomyopathy
109. Biopsie endoventriculaire droite: indications et résultats: cent seize observations
110. Differentiation of constrictive pericarditis from restrictive cardiomyopathy by computed tomographic imaging
111. Isoeffect curves for radiation-induced cardiomyopathy in the dog
112. Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction
113. Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma
114. Systemic carnitine deficiency presenting as familial endocardial fibroelastosis: a treatable cardiomyopathy
115. Hemochromatosis heart disease: an unemphasized cause of potentially reversible restrictive cardiomyopathy
116. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy
117. Transfusion hemosiderosis and chelation therapy
118. Surgical treatment of endomyocardial fibrosis
119. The cardiovascular manifestations of the hypereosinophilic syndrome prospective study of 26 patients with review of the literature
120. Right ventricular dysplasia: a report of 24 adult cases
121. Arrhythmogenic right ventricular dysplasia: clinical features, diagnostic techniques and current management
122. Right ventricular cardiomyopathy and sudden death in young people
123. Familial occurrence of right ventricular dysplasia a study involving nine families
124. Studies on the etiology, the clinical course and the prognosis of patients with dilated cardiomyopathy (DCM)
125. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy
126. Prediction of outcome in dilated cardiomyopathy
127. Cardiac hypertrophy in idiopathic dilated congestive cardiomyopathy: a clinicopathologic study
128. Familial aggregation of idiopathic cardiomyopathy
129. X-linked dilated cardiomyopathy
130. Dominantly inherited dilated cardiomyopathy
131. Autosomal recessive inheritance of idiopathic dilated cardiomyopathy in a Madeira Portuguese kindred
132. Familial idiopathic dilated cardiomyopathy
133. Cardiomyopathy associated with curly hair coat in Poll Hereford calves in Australia
134. The heart muscle in muscular dystrophy with special reference to involvement of the cardiovascular system in the hereditary myopathy of the hamster
135. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains
136. Immuno-genetic aspects of the pathogenesis of experimental viral myocardits
137. Coxsackievirus B3 myocarditis: identification of different pathogenetic mechanisms in DBA/2 and BALB/c mice
138. Hemodynamic studies in beriberi heart disease
139. The role of selenium in Keshan disease
140. An occidental case of cardiomyopathy and selenium deficiency
141. L-carnitine treatment improves cardiac performance and restores high energy phosphate pools in cardiomyopahy Syrian hamsters
142. Carnitine protection against adriamycin-induced cardiomyopathy in rats
143. Carnitinstoff-wechselveranderungen im Endstadium der dilativen Kardiomyopathie and der ischä-mischen Herzmuskelerkrankung
144. Ethanol and heart disease: an underestimated contributory factor
145. Alcoholic heart disease
146. Ultrastructural features of ethanol-induced cardiomyopathy in turkey poults
147. Ventricular function in noncardiacs with alcoholic fatty liver: the role of ethanol in the production of cardiomyopathy
148. Preclinical cardiac malfunction in chronic alcoholism: comparison with matched normal controls and with alcoholic cardiomyopathy
149. Impaired myocardial performance and response to calcium in experimental alcoholic cardiomyopathy
150. Alcohol-induced congestive cardiomyopathy in adult turkeys: effects of myocardial antioxident defence systems
151. Alcoholic cardiomyopathy
152. Verapamil prevents the development of alcoholic dysfunction in hamster myocardium
153. Alterations in DNA synthesis in cardiac tissue induced by Adriamycin in vivo—relationship to fatal toxicity
154. 10-enzymes, succinoxidase and NADH-oxidase by adriamycin and other quinones having antitumor activity
155. Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances
156. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response
157. Adriamycin cardiotoxicity: possible pathogenetic mechanisms
158. Catecholamine cardiotoxicity
159. Studies on infarct-like myocardial necrosis produced by isoproterenol: a review
160. Pheochromocytoma and cardiomyopathy
161. Reversibility of catecholamine-induced dilated cardiomyopathy in a child with a pheochromocytoma
162. Diabetic cardiomyopathy: membrane dysfunction and therapeutic strategies
163. Genetic induction of a cardiomyopathy
164. Microvascular spasm in the cardiomyopathic hamster: a preventable cause of focal myocardial necrosis
165. Coronary microvascular abnormalities in the hypertensive-diabetic rat: a primary cause of cardiomyopathy?
166. Abnormalities of the coronary microcirculation in the acute murine Chagas' disease
167. Pathophysiology of chest pain in patients with cardiomyopathies and normal coronary arteries
168. Dynamic limitation of coronary vasodilator reserve in patients with dilated cardiomyopathy and chest pain
169. Abnormal coronary hemodynamics and myocardial energetics in patients with chronic heart failure caused by ischemic heart disease and dilated cardiomyopathy
170. Auricular fibroelastosis without other evidence of heart disease a case of reversible heart failure
171. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction
172. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure
173. Congestive heart failure following chronic tachycardia
174. Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy
175. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure
176. Calcium and cardiac excitation-contraction coupling
177. Regulation of myocardial contractility, 1958–1983: an odyssey
178. Progress and problems in understanding the involvement of calcium in heart failure
179. Water and electrolyte alterations during the lifecourse of the Bio 14.6 Syrian golden hamster: a disease model of a hereditary cardiomyopathy
180. On the role of mitochondria in the hereditary cardiomyopathy of the Syrian hamster
181. 31P nuclear magnetic resonance spectroscopy: improvement after acute verapamil therapy
182. 2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats
183. 2+ transport in streptozotocin-induced diabetic cardiomyopathy in rats
184. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure
185. Davis Conference. Oxygen radicals and human disease
186. Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster
187. Failure of the antioxidant vitamin E to protect against Adriamycin-induced cardiotoxicity in the rabbit
188. Chagas' disease: a clinical epidemiologic and pathologic study
189. Chagas' disease and Chagas' syndromes the pathology of American trypanosomiasis
190. Experimental infection with Trypanosoma cruzi (Chagas' disease): a model of acute and chronic myocardiopathy
191. Pancarditis affecting the conducting system and all valves in human African trypansomiasis
192. Toxoplasmic infection in cardiac disease
193. Myocarditis as a cause of dilated cardiomyopathy
194. Adult heart disease due to coxsackie virus B infection
195. Coxsackie B myopericarditis in adults
196. Serial cardiac function tests in myocarditis
197. Arbovirus heart disease myocarditis and cardiomyopathy following dengue and chikungunya fever-a follow-up study
198. Secondary myocardial disease. Virus myocarditis and cardiomyopathy
199. Ventriculographic findings in the convalescent stage in eleven cases with acute myocarditis
200. Long-term follow-up of acute myocarditis: correlation of ventricular function and outcome
201. Idiopathic cardiomyopathy: a study of the infection immune theory as a cause of disease
202. Coxsackie group B virus and primary myocardial disease in infants and children
203. Antibodies to coxsackie B viruses in congestive cardiomyopathy
204. Myocarditis-a case of mistaken identity?
205. Congestive cardiomyopathy in association with the acquired immune deficiency syndrome
206. Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome
207. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium
208. An animal model of congestive (dilated) cardiomyopathy: dilatation and hypertrophy of the heart in the chronic stage in DBA/2 mice with myocarditis caused by encephalomyocarditis virus
209. An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice
210. Experimental herpes simplex virus carditis in mice
211. A mouse model of dilatedtype cardiomyopathy due to Coxsackie virus B3
212. Experimental coxsackievirus B-3 and B-4 myocarditis in mice
213. Myocarditis perniciosa
214. Chronic pernicious myocarditis
215. Techniques for right and left ventricular endomyocardial biopsy
216. Right ventricular endomyocardial biopsy. Clinicopathologic correlates in 100 consecutive patients
217. Diagnosis and classification of myocarditis by endomyocardial biopsy
218. High incidence of myocarditis by endomyocardial biopsy in patients with idiopathic congestive cardiomyopathy
219. Active myocarditis in the spectrum of acute dilated cardiomyopathies: clinical features, histologic correlates, and clinical outcome
220. Quantitative evaluation of inflammation in biopsy specimens from idiopathically failing or irritable hearts: experience in 80 pediatric and adult patients
221. Interobserver variability in the pathologic interpretation of endomyocardial biopsy results
222. Myocarditis: a histopathologic definition and classification
223. The role of active myocarditis in the development of heart failure in chronic Chagas' disease a study based on endomyocardial biopsies
224. The natural history of encephalomyocarditis virus-induced myositis and myocarditis in mice: viral persistence demonstrated by in situ hybridization
225. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease
226. Persistence of enterovirus RNA in dilated cardiomyopathy: a progression from myocarditis
227. The impact of recombinant DNA technology on the study of enteroviral heart disease
228. Immunologic studies of heart tissue 4: cardiac lesions in rabbits associated with autoantibodies to heart induced by immunization with heterologous heart
229. Organ specificity of the heart. 3. Circulating antibodies and immunopathological animals
230. Experimental myocarditis. 2. Cardiac lesions in rats induced by immunization with heterologous heart extracts
231. Exercise-induced augumentation of cellular and humoral autoimmunity associated with increased cardiac dilatation in experimental autoimmune myocarditis
232. American trypanosomiasis Chagas' disease
233. Antoimmune myocarditis induced by Trypanosoma cruzi
234. Experimental myocarditis induced in Swiss mice by homologous heart immunization resembles chronic experimental Chagas' heart disease
235. Viral myocarditis: a review
236. Inflammatory heart disease
237. Immunopathologic basis of myocardial injury
238. Involvement of T lymphocytes in the pathogenesis of coxsackievirus B3 heart disease
239. Coxsackievirus B-3 myocarditis. Acute and chronic forms of the disease caused by different immunopathogenic mechanisms
240. Deficient natural killer cell activity in patients with idiopathic dilated cardiomyopathy
241. Natural killer cells in dilated cardiomyopathy
242. Assessment of heart neurons in dilated (congestive) card iomyopathy
243. The collagen matrix of the heart
244. Myocardial hypertrophy in Macaca fasciculuris: structural remodeling of the collagen matrix
245. Cardiac matrix alterations induced by adriamycin
246. Functional and histopathologic correlation in patients with dilated cardiomyopathy: an integrated evaluation by multivariate analysis
247. Inadequate collagen tethers in dilated cardiomyopathy
248. Pathophysiology and current therapy of congestive heart failure
249. Current therapy of the failing heart
250. Comparison of captopril and enalapril in patients with severe chronic heart failure
251. Veterans Administration Cooperative Study on vasodilator therapy of heart failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate
252. Effects of enalapril on mortality in severe congestive heart failure Results of the cooperative North Scandinavian Enalapril Survival Study (Consensus)
253. Digitalis. Mechanisms of action and clinical use
254. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure
255. The hemodynamic and metabolic advantages gained by a three-day infusion of dobutamine in patients with congestive cardiomyopathy
256. Sustained improvement of cardiac function in patients with congestive heart failure after short-term infusion of dobutamine
257. Physiologic mechanisms governing hemodynamic responses to positive inotropic therapy in patients with dilated cardiomyopathy
258. Usefulness of calcium antagonists for congestive heart failure
259. Pharmacologic approaches to management of arrhythmias in patients with cardiomyopathy and heart failure
260. Effect of chronic β-adrenergic receptor blockade in congestive cardiomyopathy
261. Desensitization and resensitization of β-adrenergic receptors in a smooth muscle cell line
262. A randomized trial of low-dose beta-blockade therapy of idiopathic dilated cardiomyopathy
263. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind. randomized, placebo-controlled trial
264. 10
265. 10 for cardiomyopathy
266. The natural history of idiopathic dilated cardiomyopathy
267. Timing of cardiac transplantation in idiopathic dilated cardiomyopathy
268. Patient selection and results of cardiac transplantation in patients with cardiomyopathy
269. Dilated cardiomyopathy in infants and children